Macular pigment, visual function, and macular disease among subjects with alzheimer's disease: An exploratory study

Journal of Alzheimer's Disease

Volumn 42, Issue 4, 2014, Pages 1191-1202

  Nolan, John M ^a   Loskutova, Ekaterina ^a   Howard, Alan N ^b,c   Moran, Rachel ^a   Mulcahy, Riona ^d   Stack, Jim ^a   Bolger, Maggie ^d   Dennison, Jessica ^a   Akuffo, Kwadwo Owusu ^a   Owens, Niamh ^a   Thurnham, David I ^e   Beatty, Stephen ^a  

^a Ireland   (Ireland)

^b Howard Foundation   (United Kingdom)

^c DOWNING COLLEGE   (United Kingdom)

^d WATERFORD REGIONAL HOSPITAL   (Ireland)

^e UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Age related macular degeneration; Alzheimer's disease; cognitive function; contrast sensitivity; lutein; meso zeaxanthin; visual function; zeaxanthin

Indexed keywords

CAROTENOID; MESO ZEAXANTHIN; UNCLASSIFIED DRUG; VISUAL PIGMENT; XANTHOPHYLL; ZEAXANTHIN;

ADULT; AGE RELATED MACULAR DEGENERATION; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOFLUORESCENCE; BEST CORRECTED VISUAL ACUITY; BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; CONTRAST SENSITIVITY; CONTROLLED STUDY; EXPLORATORY RESEARCH; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEUROPSYCHOLOGICAL TEST; PATIENT ASSESSMENT; RETINA EXAMINATION; RETINA MACULA LUTEA; RETINA MACULOPATHY; VISION; VISUAL ACUITY; BLOOD; DIET; MACULAR DEGENERATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PSYCHOLOGY; RETINA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DIET; FEMALE; HUMANS; LUTEIN; MACULAR DEGENERATION; MACULAR PIGMENT; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RETINA; VISUAL ACUITY; ZEAXANTHINS;

EID: 84907992094     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140507     Document Type: Article

References (61)

1. Povova J, Ambroz P, Bar M, Pavukova V, Sery O, Tomaskova H, Janout V (2012) Epidemiological of and risk factors for Alzheimer's disease: A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 156, 108-114.
2. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
3. - (2012) 2012 Alzheimer's disease facts andfigures. Alzheimers Dement 8, 131-168.
4. Khachik F, Bernstein PS, Garland DL (1997) Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 38, 1802-1811.
5. Johnson EJ (2012) A possible role for lutein and zeaxanthin in cognitive function in the elderly. Am J Clin Nutr 96, 1161S-1165S.
6. Khachik F, Beecher GR, Goli MB (1991) Separation, identification and quantification of carotenoids in fruits, vegetables and human plasma by high performance liquid chromatogra-phy. Pure Appl Chem 63, 71-80.
7. Bernstein PS, Khachik F, Carvalho LS, Muir GJ, Zhao DY, Katz NB (2001) Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye. Exp Eye Res 72, 215-223.
8. Loane E, Stack J, Beatty S, Nolan JM (2007) Measurement of macular pigment optical density using two different hete-rochromatic flicker photometers. Curr Eye Res 32, 555-564.
9. Bone RA, Landrum JT, Fernandez L, Tarsis SL (1988) Analysis of the macular pigment by HPLC-Retinal distribution and age study. Invest Ophthalmol Vis Sci 29, 843-849.
10. Craft NE, Haitema TB, Garnett KM, Fitch KA, Dorey CK (2004) Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J Nutr Health Aging 8, 156-162.
11. Vishwanathan R, Neuringer M, Snodderly DM, Schalch W, Johnson EJ (2013) Macular lutein and zeaxanthin are related to brain lutein and zeaxanthin in primates. Nutr Neurosci 16, 21-29.
12. Johnson EJ, Vishwanathan R, Johnson MA, Hausman DB, Davey A, Scott TM, Green RC, Miller LS, Gearing M, Woodard J, Nelson PT, Chung HY, Schalch W, Wittwer J, Poon LW (2013) Relationship between serum and brain carotenoids, alpha-tocopherol, and retinol concentrations and cognitive performance in the oldest old from the Georgia Centenarian Study. J Aging Res 2013, 951786.
13. Rinaldi P, Polidori MC, Metastasio A, Mariani E, Mattioli P, Cherubini A, Catani M, Cecchetti R, Senin U, Mecocci P (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24, 915-919.
14. Wang W, Shinto L, Connor WE, Quinn JF (2008) Nutritional biomarkers in Alzheimer's disease: The association between carotenoids, n-3 fatty acids, and dementia severity. J Alzheimers Dis 13, 31-38.
15. Johnson EJ, McDonald K, Caldarella SM, Chung HY, Troen AM, Snodderly DM (2008) Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr Neurosci 11, 75-83.
16. Renzi LM, Iannaccone A, Johnson E, Kritchevsky S (2008) The relation between serum xanthophylls, fatty acids, macular pigment and cognitive function in the Health ABC Study. FASEB J 22, 877.5.
17. Feeney J, Finucane C, Savva GM, Cronin H, Beatty S, Nolan J, Kenny RA (2013) Low macular pigment optical density is associated with lower cognitive performance in a large population-based sample of older adults. Neurobiol Aging 34, 2449-2456.
18. Ohno-Matsui K (2011) Parallel findings in age-related macu-lar degeneration and Alzheimer's disease. Prog Retin Eye Res 30, 217-238.
19. Kaarniranta K, Salminen A, Haapasalo A, Soininen H, Hiltunen M (2011) Age-related macular degeneration (AMD): Alzheimer's disease in the eye? J Alzheimers Dis 24, 615-631.
20. Hammond BR Jr, Wooten BR (2005) CFF thresholds: Relation to macular pigment optical density. Ophthalmic Physiol Opt 25, 315-319.
21. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P (1994) Cambridge Neuropsychological Test Automated Battery (CANTAB): A factor analytic study of a large sample of normal elderly volunteers. Dementia 5, 266-281.
22. Rusted JM, Warburton DM (1988) The effects of scopo-lamine on working memory in healthy young volunteers. Psychopharmacology (Berl) 96, 145-152.
23. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, Robbins TW (1988) A comparative study of visu-ospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain 111 (Pt 3), 695-718.
24. Need AC, Attix DK, McEvoy JM, Cirulli ET, Linney KL, Hunt P, Ge D, Heinzen EL, Maia JM, Shianna KV, Weale ME, Cherkas LF, Clement G, Spector TD, Gibson G, Goldstein DB (2009) A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB. Hum Mol Genet 18, 4650-4661.
25. Yurko-Mauro K, McCarthy D, Rom D, Nelson EB, Ryan AS, Blackwell A, Salem N Jr, Stedman M (2010) Beneficialeffects of docosahexaenoic acidoncognition inage-related cognitive decline. Alzheimers Dement 6, 456-464.
26. Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Rob-bins TW (1990) Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 28, 1021-1034.
27. Charalampidou S, Nolan J, Loughman J, Stack J, Higgins G, Cassidy L, Beatty S (2011) Psychophysical impact and optical and morphological characteristics of symptomatic non-advanced cataract. Eye (Lond) 25, 1147-1154.
28. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis DM, de Jong PT, Klaver CC, Klein BE, Klein R, et al. (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39, 367-374.
29. Delori FC (2004) Autofluorescence method to measure macular pigment optical densities fluorometry and autoflu-orescence imaging. Arch Biochem Biophys 430, 156-162.
30. Dennison JL, Stack J, Beatty S, Nolan JM (2013) Concordance of macular pigment measurements obtained using customized heterochromatic flicker photometry, dual-wavelength autofluorescence, and single-wavelength reflectance. Exp Eye Res 116C, 190-198.
31. Meagher KA, Thurnham DI, Beatty S, Howard AN, Connolly E, Cummins W, Nolan JM (2012) Serum response to supplemental macular carotenoids in subjects with and without age-related macular degeneration. Br J Nutr 110, 289-300.
32. Yeum KJ, Booth SL, Sadowski JA, Liu C, Tang G, Krinsky NI, Russell RM (1996) Human plasma carotenoid response to the ingestion of controlled diets high in fruits and vegetables. Am J Clin Nutr 64, 594-602.
33. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
34. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379, 1728-1738.
35. Harman D (1992) Free radical theory of aging. Mutat Res 275, 257-266.
36. Beatty S, Koh HH, Henson D, Boulton M (2000) The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 45, 115-134.
37. Bonda DJ, Wang X, Perry G, Nunomura A, Tabaton M, Zhu X, Smith MA (2010) Oxidative stress in Alzheimer disease: A possibility for prevention. Neuropharmacology 59, 290-294.
38. Anderson DH, Mullins RF, Hageman GS, Johnson LV (2002) A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134, 411-431.
39. Walsh S, Aisen PS (2004) Inflammatory processes and Alzheimer's disease. Expert Rev Neurother 4, 793-798.
40. Qiu C (2012) Preventing Alzheimer's disease by targeting vascular risk factors: Hope and gap. J Alzheimers Dis 32, 721-731.
41. Nolan JM, Stack J, O'DO, Loane E, Beatty S (2007) Risk factors for age-related maculopathy are associated with a relative lack of macular pigment. Exp Eye Res 84, 61-74.
42. Vagnucci AH Jr, Li WW (2003) Alzheimer's disease and angiogenesis. Lancet 361, 605-608.
43. Proitsi P, Lupton MK, Dudbridge F, Tsolaki M, Hamilton G, Daniilidou M, Pritchard M, Lord K, Martin BM, Johnson J, Craig D, Todd S, McGuinness B, Hollingworth P, Harold D, Kloszewska I, Soininen H, Mecocci P, Velas B, Gill M, Lawlor B, Rubinsztein DC, Brayne C, Passmore PA, Williams J, Lovestone S, Powell JF (2012) Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiol Aging 33, 1843-17.
44. Zetterberg M, Landgren S, Andersson ME, Palmer MS, Gustafson DR, Skoog I, Minthon L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H (2008) Association of complement factor H Y402H gene polymorphism with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 147B, 720-726.
45. Klaver CC, Ott A, Hofman A, Assink JJ, Breteler MM, de Jong PT (1999) Is age-related maculopathy associated with Alzheimer's Disease? The Rotterdam Study. Am J Epidemiol 150, 963-968.
46. Clemons TE, Rankin MW, McBee WL (2006) Cognitive impairment in the Age-Related Eye Disease Study: AREDS report no. 16. Arch Ophthalmol 124, 537-543.
47. Chew E, The AREDS2 Study Group (2013) Lutein + zeaxanthin and omega-3 fatty acids for age-related mac-ular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 309, 2005-2015.
48. Beatty S, Chakravarthy U, Nolan JM, Muldrew KA, Wood-side JV, Denny F, Stevenson MR (2013) Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology 120, 600-606.
49. Loughman J, Nolan JM, Howard AN, Connolly E, Meagher K, Beatty S (2012) The impact of macular pigment augmentation on visual performance using different carotenoid formulations. Invest Ophthalmol Vis Sci 53, 7871-7880.
50. Nolan JM, Akkali MC, Loughman J, Howard AN, Beatty S (2012) Macular carotenoid supplementation in subjects with atypical spatial profiles of macular pigment. Exp Eye Res 101, 9-15.
51. Musch DC (2014) Evidence for including lutein and zeaxan-thin in oral supplements for age-related macular degeneration. JAMA Ophthalmol 132, 139-141.
52. Min JY, Min KB (2013) Serum lycopene, lutein and zeaxan-thin, and the risk of Alzheimer's disease mortality in older adults. Dement Geriatr Cogn Disord 37, 246-256.
53. Wooten BR, Hammond BR, Land RI, Snodderly DM (1999) A practical method for measuring macular pigment optical density. Invest Ophthalmol Vis Sci 40, 2481-2489.
54. Delori FC, Goger DG, Hammond BR, Snodderly DM, Burns SA (2001) Macular pigment density measured by autofluo-rescence spectrometry: Comparison with reflectometry and heterochromatic flicker photometry. J Opt Soc Am A Opt Image Sci Vis 18, 1212-1230.
55. Mathews-Roth MM, Abraham AA, Gabuzda TG (1976) Beta-carotene content of certain organs from two patients receiving high doses of beta-carotene. Clin Chem 22, 922-924.
56. Vishwanathan R, Iannaccone A, Scott TM, Kritchevsky SB, Jennings BJ, Carboni G, Forma G, Satterfield S, Harris T, Johnson KC, Schalch W, Renzi LM, Rosano C, Johnson EJ (2014) Macular pigment optical density is related to cognitive function in older people. Age Ageing 43, 271-275.
57. Scott IU, Feuer WJ, Jacko JA (2002) Impact of visual function on computer task accuracy and reaction time in a cohort of patients with age-related macular degeneration. Am J Oph-thalmol 133, 350-357.
58. Stringham JM, Garcia PV, Smith PA, McLin LN, Foutch BK (2011) Macular pigment and visual performance in glare: Benefits for photostress recovery, disability glare, and visual discomfort. Invest Ophthalmol Vis Sci 52, 7406-7415.
59. Bartlett HE, Eperjesi F (2008) A randomised controlled trial investigating the effect of lutein and antioxidant dietary supplementation on visual function in healthy eyes. Clin Nutr 27, 218-227.
60. Sasamoto Y, Gomi F, Sawa M, Tsujikawa M, Nishida K (2011) Effect of 1-year lutein supplementation on macular pigment optical density and visual function. Graefes Arch Clin Exp Ophthalmol 249, 1847-1854.
61. Sabour-Pickett S, Nolan JM, Loughman J, Beatty S (2011) A review of the evidence germane to the putative protective role of the macular carotenoids for age-related macular degeneration. Mol Nutr Food Res 56, 270-286.